The Price is Right? – Delivering UK access for niche patient populations
pharmaphorum
DECEMBER 8, 2014
With challenges to highly priced rare disease medicines and the Cancer Drug Fund evolving again – what is next, what are the ramifications for high priced/innovative treatments delivering beneficial outcomes to defined patient populations in the UK and how can pharma navigate seemingly choppy waters of access for rare disease treatments and orphan drugs?
52 
Let's personalize your content